2021
Precision medicine for mood disorders: objective assessment, risk prediction, pharmacogenomics, and repurposed drugs
Le-Niculescu H, Roseberry K, Gill SS, Levey DF, Phalen PL, Mullen J, Williams A, Bhairo S, Voegtline T, Davis H, Shekhar A, Kurian SM, Niculescu AB. Precision medicine for mood disorders: objective assessment, risk prediction, pharmacogenomics, and repurposed drugs. Molecular Psychiatry 2021, 26: 2776-2804. PMID: 33828235, PMCID: PMC8505261, DOI: 10.1038/s41380-021-01061-w.Peer-Reviewed Original ResearchConceptsBlood gene expression biomarkersTop candidate biomarkersMood disordersIndependent cohortStrongest overall evidenceBlood testsTop biomarkersGene expression biomarkersCandidate biomarkersConvergent functional genomics approachMood statesPotential new antidepressantsPsychiatric disorder patientsOverall evidenceVisual analog scaleSimple visual analog scaleMatching of patientsPanel of biomarkersPrecision medicineMonitoring of responseBipolar mood disorderExpression biomarkersCell differentiation functionsObjective assessmentSevere mania
2017
Precision medicine for suicidality: from universality to subtypes and personalization
Niculescu A, Le-Niculescu H, Levey D, Phalen P, Dainton H, Roseberry K, Niculescu E, Niezer J, Williams A, Graham D, Jones T, Venugopal V, Ballew A, Yard M, Gelbart T, Kurian S, Shekhar A, Schork N, Sandusky G, Salomon D. Precision medicine for suicidality: from universality to subtypes and personalization. Molecular Psychiatry 2017, 22: 1250-1273. PMID: 28809398, PMCID: PMC5582166, DOI: 10.1038/mp.2017.128.Peer-Reviewed Original ResearchConceptsSuicidal ideationIndependent cohortPersonalized approachFuture hospitalizationPsychiatric diagnosisCandidate biomarkersUniversal biomarkerBlood gene expression biomarkersBiology of suicideTop biomarkersNovel predictive biomarkerHigh-risk groupNon-psychiatric disordersDrug repurposing analysisPublic health problemMonitoring of responseNovel potential therapeuticsHigher suicidal ideationPredictive biomarkersClinical trialsComprehensive stepwise approachRisk groupsLarge cohortMood disordersPreventive therapeutics